{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:27:23Z","timestamp":1786116443169,"version":"build-2736575974"},"reference-count":66,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Squamous cell carcinomas (SCCs) share squamous differentiation and may engage the programmed cell death protein 1\/programmed death-ligand 1 (PD-1\/PD-L1) pathway, although their causes, biology, and treatment differ by anatomical site. We evaluated tumor response, short-term survival, and grade 3\u20134 adverse events after neoadjuvant immune-checkpoint blockade, with or without chemotherapy, followed by surgery. Methods: A comprehensive search of PubMed, Embase, the Cochrane Library, and clinical trial registries was conducted from inception to October 2024. Prospective and retrospective studies evaluating neoadjuvant immunotherapy, with or without chemotherapy, before surgery in patients with SCC were included. In mixed-histology studies, data were eligible only when SCC outcomes could be extracted separately. Pooled proportions and 95% confidence intervals (CIs) were estimated with random-effects models. Results: A total of 44 studies involving 2586 patients with six anatomical SCC groups were included. The pooled objective response rate (ORR) was 0.70 (95% CI, 0.59\u20130.80), clinical complete response (cCR) rate was 0.17 (95% CI, 0.10\u20130.28), and pathological complete response (pCR) rate was 0.30 (95% CI, 0.27\u20130.34). The pooled 1-year progression-free survival (PFS), disease-free survival (DFS), and overall survival (OS) rates were 0.82 (95% CI, 0.79\u20130.86), 0.86 (95% CI, 0.75\u20130.92), and 0.92 (95% CI, 0.90\u20130.93), respectively. The pooled incidence of grade 3\u20134 adverse events was 0.18 (95% CI, 0.14\u20130.23). Because the PD-L1 subgroup contained only one study for most outcomes, checkpoint-target subgroup findings were considered exploratory. Conclusions: Existing predominantly single-arm evidence suggests antitumor activity of neoadjuvant immune-checkpoint blockade, with or without chemotherapy, in selected patients with resectable SCC. Because esophageal SCC accounted for most studies and clinical heterogeneity was substantial, these pooled proportions should not be interpreted as comparative effects or as evidence of uniform benefit across SCC sites.<\/jats:p>","DOI":"10.3390\/jcm15156113","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:46:38Z","timestamp":1786009598000},"page":"6113","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Efficacy and Safety of Neoadjuvant Immunotherapy in Pan-Squamous Cell Carcinomas: A Meta-Analysis of Esophageal, Head and Neck, Cervical, Lung, Cutaneous, and Oral Squamous Cell Carcinomas"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3817-9175","authenticated-orcid":false,"given":"Xiaotong","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, 17 Qihelou St., Dongcheng District, Beijing 100006, China"},{"name":"Department of Neurosurgery, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuiqing","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, 17 Qihelou St., Dongcheng District, Beijing 100006, China"},{"name":"Department of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4628-8826","authenticated-orcid":false,"given":"Ming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, 17 Qihelou St., Dongcheng District, Beijing 100006, China"},{"name":"Laboratory for Clinical Medicine, Capital Medical University, 10 Toutiao, You\u2019anmenwai, Fengtai District, Beijing 100071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"ref_1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5023405","DOI":"10.1155\/2020\/5023405","article-title":"The Safety and Efficacy of Intra-Arterial versus Intravenous Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Cancer: A Meta-Analysis","volume":"2020","author":"Liu","year":"2020","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e7076","DOI":"10.1002\/cam4.7076","article-title":"Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: A systematic review and meta-analysis","volume":"13","author":"Gaber","year":"2024","journal-title":"Cancer Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/annonc\/mdt555","article-title":"Preoperative chemotherapy in advanced resectable OCSCC: Long-term results of a randomized phase III trial","volume":"25","author":"Bossi","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2020.01.008","article-title":"European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment","volume":"128","author":"Stratigos","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"Plummer","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.21037\/tcr-24-198","article-title":"Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for resectable esophageal cancer: A systematic review and meta-analysis","volume":"13","author":"Wang","year":"2024","journal-title":"Transl. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: A multicenter, phase II trial","volume":"26","author":"Uppaluri","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","article-title":"Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma","volume":"28","author":"Gulati","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: A phase 2 open-label randomized clinical trial","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin. Trials"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1996000","DOI":"10.1080\/2162402X.2021.1996000","article-title":"Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer","volume":"10","author":"Zhao","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00432-021-03896-w","article-title":"Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA\/IIIB non-small cell lung cancer: A single-arm, phase 2 trial","volume":"149","author":"Sun","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.21037\/jtd-21-340","article-title":"Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma","volume":"13","author":"Wu","year":"2021","journal-title":"J. Thorac. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.21037\/tlcr-21-130","article-title":"Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: An open-label, multicenter, single-arm study","volume":"10","author":"Duan","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-21-0585","article-title":"Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/jgo-20-599","article-title":"The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma","volume":"12","author":"Shen","year":"2021","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1186\/s12957-021-02446-5","article-title":"Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: A pilot study","volume":"19","author":"Yang","year":"2021","journal-title":"World J. Surg. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s10388-021-00899-x","article-title":"Safety and feasibility of esophagectomy following combined neoadjuvant immunotherapy and chemotherapy for locally advanced esophageal cancer: A propensity score matching","volume":"19","author":"Hong","year":"2022","journal-title":"Esophagus"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Duan, H., Shao, C., Pan, M., Liu, H., Dong, X., Zhang, Y., Tong, L., Feng, Y., Wang, Y., and Wang, L. (2022). Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE). Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.849984"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"478","DOI":"10.21037\/jgo-22-131","article-title":"Toripalimab combined with docetaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A single-center, single-arm clinical trial (ESONICT-2)","volume":"13","author":"Gao","year":"2022","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/oncolo\/oyab011","article-title":"Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma","volume":"27","author":"He","year":"2022","journal-title":"Oncologist"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Huang, S., Wu, H., Cheng, C., Zhou, M., Xu, E., Lin, W., Wang, G., Tang, J., Ben, X., and Zhang, D. (2022). Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro). Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.935374"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1186\/s13046-022-02510-2","article-title":"Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial","volume":"41","author":"Huang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e004291","DOI":"10.1136\/jitc-2021-004291","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Lv, H., Huang, C., Li, J., Zhang, F., Gai, C., Liu, Z., Xu, S., Wang, M., Li, Z., and Tian, Z. (2023). The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1100750"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Lv, H., Tian, Y., Li, J., Huang, C., Sun, B., Gai, C., Li, Z., and Tian, Z. (2022). Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.864533"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1007\/s10637-022-01293-9","article-title":"Neoadjuvant immunoradiotherapy in patients with locally advanced oral cavity squamous cell carcinoma: A retrospective study","volume":"40","author":"Shen","year":"2022","journal-title":"Investig. New Drugs"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejca.2023.03.008","article-title":"Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma","volume":"186","author":"Wang","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"doac031","DOI":"10.1093\/dote\/doac031","article-title":"Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: Real-world multicenter retrospective study in China","volume":"35","author":"Yang","year":"2022","journal-title":"Dis. Esophagus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.2147\/CMAR.S358620","article-title":"The Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study","volume":"14","author":"Yin","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","article-title":"Neoadjuvant Chemoimmunotherapy for the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Ye, J., Li, H., Gu, D., Du, M., Ai, D., Chen, W., Fang, Y., Xu, X., and Bai, C. (2022). Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1031171"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e005830","DOI":"10.1136\/jitc-2022-005830","article-title":"Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): An open-label, single-arm, phase 2 trial","volume":"11","author":"Chen","year":"2023","journal-title":"J. Immunother. Cancer."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.21037\/jtd-23-1388","article-title":"Neoadjuvant sintilimab plus chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase II clinical trial (CY-NICE)","volume":"15","author":"Chen","year":"2023","journal-title":"J. Thorac. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1007\/s00262-023-03550-z","article-title":"PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: A retrospective study","volume":"72","author":"Fang","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1097\/JS9.0000000000000489","article-title":"Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: A prospective single-arm trial (Illuminate Trial)","volume":"109","author":"Huang","year":"2023","journal-title":"Int. J. Surg."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/cncr.34930","article-title":"A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma","volume":"129","author":"Patel","year":"2023","journal-title":"Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Wang, K., Gui, L., Lu, H., He, X., Li, D., Liu, C., Liu, S., and Wang, X. (2023). Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1189752"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wang, Q., Qi, C., Luo, J., Xu, N., Xu, M.T., Qiang, Y., Zhang, C., and Shen, Y. (2023). Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC). Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1239451"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1007\/s00262-023-03557-6","article-title":"Evaluation of neoadjuvant chemotherapy combined with PD-1 inhibitors in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma: A comparative study of antitumor activity","volume":"72","author":"Xu","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/s41591-023-02469-3","article-title":"Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: A phase 1b trial","volume":"29","author":"Yin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.21037\/tlcr-22-871","article-title":"Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: A retrospective cohort study","volume":"12","author":"Zhao","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Zhou, R.Q., Luo, J., Li, L.J., Du, M., and Wu, Q.C. (2023). Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: A retrospective cohort study. BMC Surg., 23.","DOI":"10.1186\/s12893-023-02023-5"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"112558","DOI":"10.1016\/j.intimp.2024.112558","article-title":"Efficacy, safety, and survival of neoadjuvant immunotherapy plus chemotherapy in locally advanced esophageal squamous cell carcinoma: A real-world retrospective study","volume":"138","author":"Guo","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"znad363","DOI":"10.1093\/bjs\/znad363","article-title":"Complete responses after neoadjuvant toripalimab and chemoradiotherapy for oesophageal squamous cell carcinoma: In situ and ex vivo 3.0\u2005T MRI assessment","volume":"111","author":"Zhao","year":"2024","journal-title":"Br. J. Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1001\/jamaoto.2024.0259","article-title":"Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma","volume":"150","author":"Kim","year":"2024","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13019-024-02500-9","article-title":"Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III-IVA esophageal squamous cell carcinoma post-surgery","volume":"19","author":"Li","year":"2024","journal-title":"J. Cardiothorac. Surg."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(23)00531-4","article-title":"Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): A multicentre, single-arm, phase 2 trial","volume":"25","author":"Li","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.21037\/jtd-24-169","article-title":"Real-world retrospective study of anti-PD-1 antibody in combination with chemotherapy as a neoadjuvant treatment strategy for locally advanced resectable esophageal squamous cell carcinoma","volume":"16","author":"Liu","year":"2024","journal-title":"J. Thorac. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s00432-024-05793-4","article-title":"Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma","volume":"150","author":"Lv","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4143\/crt.2023.897","article-title":"Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study","volume":"56","author":"Park","year":"2024","journal-title":"Cancer Res. Treat."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00262-023-03579-0","article-title":"Retrospective assessment of neoadjuvant camrelizumab combined with induction chemotherapy: Efficacy in laryngeal preservation for advanced hypopharyngeal and laryngeal squamous cell carcinoma","volume":"73","author":"Peng","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"15330338241231610","DOI":"10.1177\/15330338241231610","article-title":"Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma","volume":"23","author":"Qian","year":"2024","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"573","DOI":"10.17219\/acem\/170265","article-title":"Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study","volume":"33","author":"Wang","year":"2024","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e008631","DOI":"10.1136\/jitc-2023-008631","article-title":"Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer","volume":"12","author":"Xu","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1097\/JS9.0000000000000978","article-title":"Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: A single-arm phase 2 study (cohort study)","volume":"110","author":"Yang","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1470-2045(23)00459-X","article-title":"Neoadjuvant cemiplimab and surgery for stage II\u2013IV cutaneous squamous-cell carcinoma: Follow-up and survival outcomes of a single-arm, multicentre, phase 2 study","volume":"24","author":"Gross","year":"2023","journal-title":"Lancet Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/6113\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T10:15:44Z","timestamp":1786011344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/6113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":66,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15156113"],"URL":"https:\/\/doi.org\/10.3390\/jcm15156113","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}